Longevity.Technology publishes report on atherosclerosis and Cyclarity’s novel approach

CTX-Longevity.Technology-report-1.2-o

We invite you to read the Longevity.Technology report “Disease management to disease modification – removing plaque to undo atherosclerosis”.

This detailed report highlights:

  • Atherosclerosis disease profile – accounting for over 40% of all deaths worldwide.
  • Current treatments that fail to address the underlying cause of the disease, or reverse the atherosclerotic plaques already formed. 
    Cyclarity’s novel “disease-modifying” solution to repair an underlying cause of many age related diseases, removing toxic biomolecules from inside cells.
  • Cyclarity’s primary candidate, UDP-003 a beta-cyclodextrin designed to target and remove toxic, oxidized cholesterol.
  • The potential promise for investors, healthcare systems in the US and globally, and, most of all, for those affected by atherosclerosis-related disease.
The report concludes:

Cyclarity’s approach to true disease medication, and therefore reversal of age-related disease, without doubt, offers a great deal of promise for investors, for healthcare systems in the US and globally, and most of all for those affected by atherosclerosis-related disease.

. . . this may be the perfect opportunity for Cyclarity to enter the field, as it is one of the few solutions available that addresses the limiting factors of previous therapies both from a scientific perspective and from a market perspective.

We’re thrilled to be working towards reversing the world’s leading killer and thankful to Longevity.Technology for bringing a focus to our novel treatment.

About Cyclarity

Cyclarity Therapeutics, Inc., is pursuing a mission to treat the underlying causes of age-related disease. The company develops simple and direct interventions targeting oxidized cholesterol using rationally designed molecules, to provide the first true disease-modifying treatments for common age-related conditions such as atherosclerosis, heart attack and stroke. Its products are based on novel derivatives of a well-known, safe compound and a new way of looking at cardiovascular disease. For more information, please visit www.underdogpharma.com or send an email to press@cyclaritytx.com

Forward Looking Statements

The information and statements contained herein contain forward-looking statements, which are subject to risks and uncertainties that could cause actual results to differ materially from such forward-looking statements and should not be considered as an indication or guarantee of future performance. Forward-looking statements involve known and unknown risks and uncertainties which could cause the Company’s prospects or actual results to differ materially from those in the forward-looking statements. The Company does not undertake any obligation to update the information or forward-looking statements contained herein whether as a result of new information or future events or otherwise.

Contact:

Mike Kope
CEO of Corporate Affairs
Cyclarity Therapeutics, Inc.
press@cyclaritytx.com

Cyclarity News:

KIZOO Technology Capital owner Michael Greve discusses recent scientific advancements with Drug Discovery World

KIZOO Technology Capital owner Michael Greve discusses the recent scientific advancements in addressing the root causes of age-related diseases in the rejuvenation biotechnology sphere—including the work of Underdog Pharmaceuticals. As one of Kizoo’s key startups, Underdog’s goal is to deliver affordable therapeutics for the prevention of heart disease and stroke through the removal of arterial plaque.

Read More »

Kizoo Portfolio Company Underdog Closes $10M Financing Round

Underdog Pharmaceuticals, a key investment of Michael Greve’s rejuvenation biotech VC Kizoo, has closed a $10 million round of capital. Kizoo led the company’s Series Seed II round, which saw participation from both existing and new investors.

Underdog was recently awarded the Innovation Passport under the United Kingdom’s Innovative Licensing and Access Pathway (ILAP). This will enable faster patient access to its groundbreaking treatment for the prevention of heart attacks and stroke. The company expects to begin clinical trials in 2023.

Read More »